Veralox is developing first-in-class therapeutics targeting 12-lipoxygenase (12-LOX), initially for the treatment of heparin-induced thrombocytopenia and thrombosis (HITT). The company’s lead drug has potential to be a game-changer in the treatment of HITT based on predicted clinical outcomes (efficacy, safety, and healthcare economics).